A patient with new-onset atrial fibrillation and a CHA2DS2-VASc score of 2. What is the recommended long-term strategy to reduce stroke risk?

• A. Begin oral anticoagulation with a DOAC or warfarin (target INR 2–3) after bleeding risk assessment.
• B. Use antiplatelet therapy alone (aspirin)
• C. No therapy due to moderate risk
• D. Rate-control therapy only

Answer: (A)

Anticoagulation to prevent cardioembolic stroke in atrial fibrillation is guided by the CHA2DS2-VASc score. A score of 2 indicates enough annual stroke risk to justify long-term anticoagulation, assuming there are no contraindications. Starting an oral anticoagulant markedly lowers stroke risk compared with antiplatelet therapy or no therapy.

Choosing a DOAC (like apixaban, rivaroxaban, dabigatran, or edoxaban) or warfarin with a target INR of 2–3 offers superior protection against stroke in nonvalvular AF and generally has a favorable safety profile, especially regarding intracranial bleeding, compared with aspirin alone. Bleeding risk should be assessed and modifiable factors addressed, but a high bleeding risk does not automatically rule out anticoagulation; it informs the choice and monitoring plan.

Rate-control therapy helps manage symptoms and heart rate but does not reduce stroke risk, which is why it’s not the long-term strategy to prevent embolic events. No therapy leaves the patient at ongoing risk, and antiplatelet therapy alone is less effective for stroke prevention in AF.

So the recommended long-term strategy is to begin an oral anticoagulant, either a DOAC or warfarin (target INR 2–3) after evaluating bleeding risk.